In the last decade, many studies have focused on the clinical relevance of anti-DFS70 antibodies [reviewed in (5)] and their prevalence has been reported in some chronic inflammatory diseases (2, 11, 12) and cancers [e.g. prostate cancer (13, 14)], but still no clear disease association has been found. The gene discussed is PSIP1; the disease is prostate cancer.